Hyperfine (HYPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, to be held virtually via live audio webcast.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of five directors: Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Hyperfine
- Q1 2026 revenue surged 83% to $3.9M, with gross margin at 51% and cash runway into 2028.HYPR
Q1 202612 May 2026 - Up to 1,083,335 shares registered for resale, with proceeds from warrant exercises funding operations.HYPRRegistration filing12 May 2026
- Director elections, auditor ratification, and executive pay updates under controlled company governance.HYPRProxy filing14 Apr 2026
- Q4 2025 revenue up 128% year-over-year; 2026 guidance targets 55% growth and margin gains.HYPRQ4 202519 Mar 2026
- Record Q2 revenue, raised 2024 guidance, and global expansion signal accelerating growth.HYPRQ2 20242 Feb 2026
- Portable AI-powered brain MRI drives growth and expands access in neurology care.HYPRJefferies Global Healthcare Conference1 Feb 2026
- Portable brain MRI drives clinical and financial growth, targeting stroke and Alzheimer's markets.HYPRH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- AI-powered portable MRI drives growth, access, and efficiency in brain imaging markets.HYPRInvestor presentation20 Jan 2026
- Q3 revenue up 56% with record margins; global expansion and AI innovation fuel growth.HYPRQ3 202414 Jan 2026